Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients

Abstract

We confirmed the prognostic utility of cfDNA quantitative analysis in SCLC patients before and during therapy. Our novel risk prognostic model in clinical practice will allow to identify patients who could benefit with actual therapies.